Merck Granted Breakthrough Therapy Designations To Treat HCV
Hepatitis C, News
Merck (MSD) has recently announced that grazoprevir/elbasvir, which is a single tablet investigational regimen to treat chronic hepatitis C virus (HCV) infection, has received two Breakthrough Therapy designations granted by the United Stated Food and Drug Administration ... Read more